Katrien Berns

Katrien Berns

Auto-generated profile, based on publicly available information

Katrien Berns

Division of Molecular Carcinogenesis, Oncode Institute, Cancer Genomics Center Netherlands, the Netherlands Cancer Institute, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2018 in Oncogene
Verified
Journal Article
Open access
PDF file
KBKatrien Berns
Katrien Berns
JCJoseph J. Caumanns
Joseph J. Caumanns
EHE. Marielle Hijmans
E. Marielle Hijmans
AGAnnemiek M. C. Gennissen
Annemiek M. C. Gennissen
TSTesa M. Severson
Tesa M. Severson
RBRené Bernards
René Bernards
Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of ovarian clear cell carcinomas. To search for a rational approach to target ovarian clear cell cancers with ARID1A mutations, we performed kinome-centered lethality screens in a large panel of ovarian clear cell carcinoma cell lines. Using the largest OCCC cell line panel established to date, we show here that BRD2 inhibition is predominantly lethal in ARID1A mutated ovarian clear cell cancer cells. Importantly, small molecule inhibitors of the BET (bromodomain and extra terminal domain) family of proteins, to which BRD2 belongs, specifically inhibit proliferation of ARID1A mutated cell lines, both in vitro and in ovarian clear cell cancer xenografts and patient-derived xenograft models. BET inhibitors cause a reduction in the expression of multiple SWI/SNF members including ARID1B, providing a potential explanation for the observed lethal interaction with ARID1A loss. Our data indicate that BET inhibition may represent a novel treatment strategy for a subset of ARID1A mutated ovarian clear cell carcinomas.

1 February 2017 in Cancer Cell
Verified
Journal Article
Closed access
KBKatrien Berns
Katrien Berns
ABAnton Berns
Anton Berns

5 October 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
MFMarta Llaurado Fernandez
Marta Llaurado Fernandez
EHE. Marielle Hijmans
E. Marielle Hijmans
AGAnnemiek M.C. Gennissen
Annemiek M.C. Gennissen
NWNelson Wong
Nelson Wong
SLShang Li
Shang Li
KBKatrien Berns
Katrien Berns
Low-grade serous ovarian cancer (LGSOC) is a rare subtype of epithelial ovarian cancer with high fatality rates in advanced stages due to its chemoresistant properties. LGSOC is characterized by activation of MAPK signaling, and recent clinical trials indicate that the MEK inhibitor (MEKi) trametinib may be a good treatment option for a subset of patients. Understanding MEKi-resistance mechanisms and subsequent identification of rational drug combinations to suppress resistance may greatly improve LGSOC treatment strategies. Both gain-of-function and loss-of-function CRISPR-Cas9 genome-wide libraries were used to screen LGSOC cell lines to identify genes that modulate the response to MEKi. Overexpression of MAML2 and loss of MAP3K1 were identified, both leading to overexpression of the NOTCH target HES1, which has a causal role in this process as its knockdown reversed MEKi resistance. Interestingly, increased HES1 expression was also observed in selected spontaneous trametinib-resistant clones, next to activating MAP2K1 (MEK1) mutations. Subsequent trametinib synthetic lethality screens identified SHOC2 downregulation as being synthetic lethal with MEKis. Targeting SHOC2 with pan-RAF inhibitors (pan-RAFis) in combination with MEKi was effective in parental LGSOC cell lines, in MEKi-resistant derivatives, in primary ascites cultures from patients with LGSOC, and in LGSOC (cell line–derived and patient-derived) xenograft mouse models. We found that the combination of pan-RAFi with MEKi downregulated HES1 levels in trametinib-resistant cells, providing an explanation for the synergy that was observed. Combining MEKis with pan-RAFis may provide a promising treatment strategy for patients with LGSOC, which warrants further clinical validation.

3 April 2023
Verified
Other
Open access
MFMarta Llaurado Fernandez
Marta Llaurado Fernandez
EHE. Marielle Hijmans
E. Marielle Hijmans
AGAnnemiek M.C. Gennissen
Annemiek M.C. Gennissen
NWNelson Wong
Nelson Wong
SLShang Li
Shang Li
KBKatrien Berns
Katrien Berns
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

3 April 2023
Verified
Other
Open access
MFMarta Llaurado Fernandez
Marta Llaurado Fernandez
EHE. Marielle Hijmans
E. Marielle Hijmans
AGAnnemiek M.C. Gennissen
Annemiek M.C. Gennissen
NWNelson Wong
Nelson Wong
SLShang Li
Shang Li
KBKatrien Berns
Katrien Berns
Supplementary Figure from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition